These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31864502)

  • 1. Hyponatremia in a Patient With Cancer.
    Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
    Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
    Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract]   [Full Text] [Related]  

  • 3. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective hypopituitarism with severe hyponatremia and secondary hyporeninism.
    Major P; Kuchel O; Boucher R; Nowaczynski W; Genest J
    J Clin Endocrinol Metab; 1978 Jan; 46(1):15-9. PubMed ID: 221513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal crisis presented as acute onset of hypercalcemia and hyponatremia triggered by acute pyelonephritis in a patient with partial hypopituitarism and pre-dialysis chronic kidney disease.
    Yamada S; Arase H; Morishita T; Tsuchimoto A; Torisu K; Torisu T; Tsuruya K; Nakano T; Kitazono T
    CEN Case Rep; 2019 May; 8(2):83-88. PubMed ID: 30456557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypopituitarism with water intoxication and coma: favorable outcome following early treatment.
    Luboshitzky R; Sobel JD; Kurtzbaum A; Better OS; Spitz IM
    J Endocrinol Invest; 1979; 2(4):423-6. PubMed ID: 119801
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 9. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H; Zhang L; Liu W
    J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolution of stiff-man syndrome with cortisol replacement in a patient with deficiencies of ACTH, growth hormone, and prolactin.
    George TM; Burke JM; Sobotka PA; Greenberg HS; Vinik AI
    N Engl J Med; 1984 Jun; 310(23):1511-3. PubMed ID: 6325914
    [No Abstract]   [Full Text] [Related]  

  • 11. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C; Sampaio L; Fernandes G
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract]   [Full Text] [Related]  

  • 13. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases.
    Diederich S; Franzen NF; Bähr V; Oelkers W
    Eur J Endocrinol; 2003 Jun; 148(6):609-17. PubMed ID: 12773132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyponatremia, a frequent, and at times a major and indicative sign in anterior pituitary insufficiency].
    Eulry F; Berthezene F
    Ann Endocrinol (Paris); 1978; 39(1):53-4. PubMed ID: 207218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I; Chernoff M
    Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract]   [Full Text] [Related]  

  • 18. Beyond semantics: defining hyponatremia in secondary adrenal insufficiency.
    Faustini-Fustini M; Anagni M
    J Endocrinol Invest; 2006 Mar; 29(3):267-9. PubMed ID: 16682844
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism.
    Oelkers W
    N Engl J Med; 1989 Aug; 321(8):492-6. PubMed ID: 2548097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.